Skip Navigation



Hum. Reprod. Advance Access published online on December 23, 2004
Human Reproduction, doi:10.1093/humrep/deh711
This Article
Right arrow FREE Full Text (PDF ) Freely available
Right arrow All Versions of this Article:
20/4/936    most recent
deh711v2
deh711v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Harris, H. A.
Right arrow Articles by Richard Lyttle, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Harris, H. A.
Right arrow Articles by Richard Lyttle, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Reproduction © European Society of Human Reproduction and Embryology 2004; all rights reserved
Received October 21, 2004
Revised November 30, 2004
Accepted December 3, 2004

Article

A selective estrogen receptor-{beta} agonist causes lesion regression in an experimentally induced model of endometriosis

Heather A. Harris 1*, Kaylon L. Bruner-Tran 2, Xiaochun Zhang 1, Kevin G. Osteen 2, and C. Richard Lyttle 1

1 Women's Health Research Institute, Wyeth Research, Collegeville, PA 19426, USA
2 Department of Obstetrics and Gynecology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA

* To whom correspondence should be addressed.
Heather A. Harris, E-mail: harrish{at}wyeth.com


  Abstract

BACKGROUND: Endometriosis is a common gynaecological problem of uncertain aetiology. It affects primarily young, reproductive-aged women and can result in chronic pelvic pain and infertility. Current approved therapies have significant side-effects and hysterectomy is employed as a final solution. ERB-041 is a selective estrogen receptor-{beta} (ER{beta}) agonist that has anti-inflammatory activity in preclinical models of arthritis and inflammatory bowel disease, but is inactive in many preclinical models of classic estrogen activity. Because endometriosis is now thought to be, at least in part, an inflammatory disease, we evaluated ERB-041's activity in an experimentally induced model of endometriosis. METHODS: Athymic nude mice (ovariectomized or intact) were implanted with tissue fragments of normal human endometrium. After establishment of lesions for 11-14 days, mice were treated with ERB-041 for 15-17 days. Upon euthanasia, the number of lesions, their size and location were noted. Five lesions were recovered for RNA analysis. RESULTS: Across six studies, ERB-041 caused complete lesion regression in 40-75% of the mice studied. The compound appeared to be equally effective in gonad-intact as in ovariectomized mice, and analysed recovered lesions expressed ER{alpha} but not ER{beta} mRNA. CONCLUSIONS: ERB-041 and possibly other ER{beta} selective agonists may be a useful new approach to treating endometriosis.

Keywords: endometriosis; ERB-041; estrogen receptor-{beta}; immune system; nude mouse.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 EndocrinologyHome page
O. Bukulmez, D. B. Hardy, B. R. Carr, R. A. Word, and C. R. Mendelson
Inflammatory Status Influences Aromatase and Steroid Receptor Expression in Endometriosis
Endocrinology, March 1, 2008; 149(3): 1190 - 1204.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. Cvoro, D. Tatomer, M.-K. Tee, T. Zogovic, H. A. Harris, and D. C. Leitman
Selective Estrogen Receptor- Agonists Repress Transcription of Proinflammatory Genes
J. Immunol., January 1, 2008; 180(1): 630 - 636.
[Abstract] [Full Text] [PDF]

Home page
 Biol. Reprod.Home page
Q. Xue, Z. Lin, Y.-H. Cheng, C.-C. Huang, E. Marsh, P. Yin, M. P Milad, E. Confino, S. Reierstad, J. Innes, et al.
Promoter Methylation Regulates Estrogen Receptor 2 in Human Endometrium and Endometriosis
Biol Reprod, October 1, 2007; 77(4): 681 - 687.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
H. A. Harris
Estrogen Receptor-{beta}: Recent Lessons from in Vivo Studies
Mol. Endocrinol., January 1, 2007; 21(1): 1 - 13.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
K. L. Bruner-Tran, Z. Zhang, E. Eisenberg, R. C. Winneker, and K. G. Osteen
Down-Regulation of Endometrial Matrix Metalloproteinase-3 and -7 Expression in Vitro and Therapeutic Regression of Experimental Endometriosis in Vivo by a Novel Nonsteroidal Progesterone Receptor Agonist, Tanaproget
J. Clin. Endocrinol. Metab., April 1, 2006; 91(4): 1554 - 1560.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
S. Defrere, A. Van Langendonckt, R. G. Ramos, M. Jouret, M. Mettlen, and J. Donnez
Quantification of endometriotic lesions in a murine model by fluorimetric and morphometric analyses
Hum. Reprod., March 1, 2006; 21(3): 810 - 817.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
F. Chen, K. Knecht, E. Birzin, J. Fisher, H. Wilkinson, M. Mojena, C. T. Moreno, A. Schmidt, S.-i. Harada, L. P. Freedman, et al.
Direct Agonist/Antagonist Functions of Dehydroepiandrosterone
Endocrinology, November 1, 2005; 146(11): 4568 - 4576.
[Abstract] [Full Text] [PDF]

Home page
 Biol. Reprod.Home page
O. Imamov, G.-J. Shim, M. Warner, and J.-A. Gustafsson
Estrogen Receptor beta in Health and Disease
Biol Reprod, November 1, 2005; 73(5): 866 - 871.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.